Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P N Durrington

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
Atherosclerosis|June 24, 2003
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart diseaseS S Soedamah-Muthu, H M Colhoun, M J Thomason, et al.
Heart (British Cardiac Society)|November 18, 2004
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemiaH A W Neil, V Seagroatt, D J Betteridge, et al.
Atherosclerosis|November 20, 2009
Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populationsJ V Patel, M J Caslake, A Vyas, et al.
Nature Genetics|February 2, 2000
LMNA, encoding lamin A/C, is mutated in partial lipodystrophyS Shackleton, D J Lloyd, S N Jackson, et al.
Diabetologia|October 31, 2008
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)V Charlton-Menys, D J Betteridge, H Colhoun, et al.
The Cochrane Database of Systematic Reviews|October 21, 2004
Omega 3 fatty acids for prevention and treatment of cardiovascular diseaseL Hooper, R L Thompson, R A Harrison, et al.
Journal of Medical Genetics|December 5, 2006
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease riskS E Humphries, R A Whittall, C S Hubbart, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 21, 2010
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1)M K Rutter, H R Prais, V Charlton-Menys, et al.
Journal of Internal Medicine|February 16, 2006
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panelP J Barter, C M Ballantyne, R Carmena, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Atherosclerosis|June 24, 2003
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart diseaseS S Soedamah-Muthu, H M Colhoun, M J Thomason, et al.
Heart (British Cardiac Society)|November 18, 2004
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemiaH A W Neil, V Seagroatt, D J Betteridge, et al.
Atherosclerosis|November 20, 2009
Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populationsJ V Patel, M J Caslake, A Vyas, et al.
Nature Genetics|February 2, 2000
LMNA, encoding lamin A/C, is mutated in partial lipodystrophyS Shackleton, D J Lloyd, S N Jackson, et al.
Diabetologia|October 31, 2008
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)V Charlton-Menys, D J Betteridge, H Colhoun, et al.
The Cochrane Database of Systematic Reviews|October 21, 2004
Omega 3 fatty acids for prevention and treatment of cardiovascular diseaseL Hooper, R L Thompson, R A Harrison, et al.
Journal of Medical Genetics|December 5, 2006
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease riskS E Humphries, R A Whittall, C S Hubbart, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 21, 2010
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1)M K Rutter, H R Prais, V Charlton-Menys, et al.
Journal of Internal Medicine|February 16, 2006
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panelP J Barter, C M Ballantyne, R Carmena, et al.
Pageof 19